ARS Pharmaceuticals (SPRY) Research & Development (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Research & Development of $4.3 million for Q1 2026, up 25.94% sequentially from $3.4 million in Q4 2025, and up 46.88% YoY from $3.0 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Research & Development (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Research & Development for 7 years, with the latest figure at $4.3 million in Q1 2026.
- Quarterly Research & Development rose 46.88% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (down 15.8% YoY) and the FY2025 annual result came in at $13.2 million, down 32.68% from the prior year.
- Research & Development climbed to $4.3 million in Q1 2026 per SPRY's latest filing, from $3.4 million in the prior quarter.
- Over five years, Research & Development peaked at $7.3 million in Q2 2023 and troughed at $2.8 million in Q3 2025.
- A 5-year average of $4.5 million and a median of $4.3 million in 2026 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 118.57% in 2022, down 75.49% in 2022.
- Over 5 years, Research & Development stood at $4.7 million in 2022, then decreased by 27.73% to $3.4 million in 2023, then retreated by 11.08% to $3.0 million in 2024, then gained by 13.74% to $3.4 million in 2025, then increased by 25.94% to $4.3 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $4.3 million, $3.4 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 4.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.70 Mn |
| Mar 31, 2026 | 4.34 Mn |
| Dec 31, 2025 | 3.44 Mn |
| Sep 30, 2025 | 2.75 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | 2.95 Mn |
| Dec 31, 2024 | 3.03 Mn |
| Sep 30, 2024 | 4.42 Mn |
| Jun 30, 2024 | 6.90 Mn |
| Mar 31, 2024 | 5.23 Mn |
| Dec 31, 2023 | 3.40 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 7.31 Mn |
| Mar 31, 2023 | 6.55 Mn |
| Dec 31, 2022 | 4.71 Mn |
| Sep 30, 2022 | 3.89 Mn |
| Jun 30, 2022 | 4.35 Mn |
| Mar 31, 2022 | 5.42 Mn |
| Dec 31, 2021 | -25.36 Mn |
| Sep 30, 2021 | 15.64 Mn |